GlaxoSmithKline Pharmaceuticals Limited has announced its audited financial results for the year ended March 31, 2026, reporting a consolidated profit of Rs. 103,598 lakhs. The Board of Directors has recommended a final dividend of Rs. 57 per equity share, subject to shareholder approval at the upcoming 101st Annual General Meeting scheduled for June 30, 2026. The record date for dividend eligibility has been set for May 29, 2026.
Financial Performance Overview
For the financial year ended March 31, 2026, the company achieved a strong financial performance. The consolidated revenue from operations reached Rs. 382,167 lakhs, contributing to a total profit for the year of Rs. 103,598 lakhs. On a standalone basis, the company reported revenue from operations of Rs. 379,020 lakhs with a net profit of Rs. 101,182 lakhs.
Dividend and Annual General Meeting
The Board of Directors has proposed a final dividend of Rs. 57 per equity share, having a face value of Rs. 10 each. This recommendation is subject to the approval of members at the 101st Annual General Meeting, which is slated to be held on Tuesday, June 30, 2026, via video conferencing. Shareholders eligible for this dividend will be determined based on the record date of Friday, May 29, 2026.
Strategic Corporate Updates
The company confirmed that it does not qualify as a Large Corporate entity as of March 31, 2026, as it has no outstanding long-term borrowings exceeding Rs. 1,000 crores, nor has it issued debt securities. Additionally, the company noted that the impact of new Labour Codes resulted in a Rs. 1,182 lakh increase in employee benefit expenses for the fiscal year, primarily due to updated wage definitions.
Source: BSE
